A Pan-Cancer Analysis of the Oncogenic Role of Integrin Beta4 (ITGB4) in Human Tumors.
ITGB4
cancer
methylation
phosphorylation
prognosis
Journal
International journal of general medicine
ISSN: 1178-7074
Titre abrégé: Int J Gen Med
Pays: New Zealand
ID NLM: 101515487
Informations de publication
Date de publication:
2021
2021
Historique:
received:
18
10
2021
accepted:
30
11
2021
entrez:
20
12
2021
pubmed:
21
12
2021
medline:
21
12
2021
Statut:
epublish
Résumé
Integrin beta4 (ITGB4) is a transmembrane receptor that plays a key role in tumorigenesis and tumor development. However, there are no pan-cancer analyses of ITGB4. This study demonstrates the first potential oncogenic roles of ITGB4 across 33 tumors based on the dataset of the Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO). ITGB4 is highly expressed in many cancers, and distinct correlations exist between ITGB4 expression and the prognosis of tumor patients. We also found that the methylation and genetic alteration level of ITGB4 was associated with some cancer prognosis. Furthermore, we found a reduced phosphorylation of ITGB4 at S1457 in several tumors, such as breast and ovarian cancers. Finally, ITGB4 expression was correlated with cancer-associated fibroblasts in liver hepatocellular carcinoma and prostate adenocarcinoma, and the infiltration level of NK cells and neutrophils was observed in other cancers, such as breast invasive carcinoma and lung adenocarcinoma. Moreover, RNA metabolism and protein processing-associated functions are involved in the functional mechanism of ITGB4. Our first pan-cancer study may offer a relatively comprehensive understanding of the oncogenic roles of ITGB4 across different tumors.
Sections du résumé
BACKGROUND
BACKGROUND
Integrin beta4 (ITGB4) is a transmembrane receptor that plays a key role in tumorigenesis and tumor development. However, there are no pan-cancer analyses of ITGB4.
METHODS
METHODS
This study demonstrates the first potential oncogenic roles of ITGB4 across 33 tumors based on the dataset of the Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO).
RESULTS
RESULTS
ITGB4 is highly expressed in many cancers, and distinct correlations exist between ITGB4 expression and the prognosis of tumor patients. We also found that the methylation and genetic alteration level of ITGB4 was associated with some cancer prognosis. Furthermore, we found a reduced phosphorylation of ITGB4 at S1457 in several tumors, such as breast and ovarian cancers. Finally, ITGB4 expression was correlated with cancer-associated fibroblasts in liver hepatocellular carcinoma and prostate adenocarcinoma, and the infiltration level of NK cells and neutrophils was observed in other cancers, such as breast invasive carcinoma and lung adenocarcinoma. Moreover, RNA metabolism and protein processing-associated functions are involved in the functional mechanism of ITGB4.
CONCLUSION
CONCLUSIONS
Our first pan-cancer study may offer a relatively comprehensive understanding of the oncogenic roles of ITGB4 across different tumors.
Identifiants
pubmed: 34924769
doi: 10.2147/IJGM.S341076
pii: 341076
pmc: PMC8674675
doi:
Types de publication
Journal Article
Langues
eng
Pagination
9629-9645Informations de copyright
© 2021 Huang et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work and have declared that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Cancer Res. 1995 Feb 15;55(4):901-6
pubmed: 7850807
BMC Bioinformatics. 2014 Aug 29;15:293
pubmed: 25176396
Cancer Biother Radiopharm. 2020 Nov 11;:
pubmed: 33179959
Sci Rep. 2015 Jul 30;5:12642
pubmed: 26223322
Neoplasia. 2017 Aug;19(8):649-658
pubmed: 28732212
Nat Biotechnol. 2006 Oct;24(10):1285-92
pubmed: 16964243
Oral Surg Oral Med Oral Pathol Oral Radiol. 2012 Nov;114(5 Suppl):S41-5
pubmed: 23083954
Oncogene. 2018 Jul;37(30):4164-4180
pubmed: 29706653
Bioinformatics. 2019 Jul 15;35(14):i436-i445
pubmed: 31510660
J Cell Mol Med. 2020 Nov;24(22):13481-13493
pubmed: 33073486
Genome Res. 2019 Apr;29(4):543-553
pubmed: 30782641
Annu Rev Cell Dev Biol. 2003;19:173-206
pubmed: 14570568
Cancer. 2008 Mar 15;112(6):1272-81
pubmed: 18224668
Nat Rev Drug Discov. 2019 Feb;18(2):99-115
pubmed: 30470818
Genome Biol. 2007;8(5):215
pubmed: 17543136
Epigenetics Chromatin. 2018 Jun 29;11(1):37
pubmed: 29958539
Surg Oncol Clin N Am. 2001 Apr;10(2):313-28, viii-ix
pubmed: 11382589
JCO Precis Oncol. 2017;2017:
pubmed: 29850653
Lab Invest. 2015 Mar;95(3):308-19
pubmed: 25599535
Oncogene. 2018 Feb 8;37(6):744-755
pubmed: 29059156
Open Biol. 2019 Aug 30;9(8):190148
pubmed: 31409231
Sci Rep. 2017 Jan 13;7:40464
pubmed: 28084395
Biochem Biophys Res Commun. 2012 Oct 26;427(3):642-8
pubmed: 23026047
Signal Transduct Target Ther. 2020 Aug 11;5(1):147
pubmed: 32782265
Cancer Cell Int. 2018 Apr 2;18:50
pubmed: 29618949
Nat Rev Cancer. 2018 Sep;18(9):533-548
pubmed: 30002479
Physiol Rev. 2003 Jul;83(3):673-86
pubmed: 12843406
Cancer Sci. 2018 Dec;109(12):3695-3706
pubmed: 30264476
Carcinogenesis. 2008 Jul;29(7):1394-9
pubmed: 18550570
R Soc Open Sci. 2018 Dec 5;5(12):181006
pubmed: 30662724
Oncogene. 2020 Jan;39(3):664-676
pubmed: 31534187
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
J Neurosci. 2008 Oct 29;28(44):11292-303
pubmed: 18971471
Signal Transduct Target Ther. 2020 Apr 22;5(1):39
pubmed: 32317629
Bosn J Basic Med Sci. 2020 Feb 05;20(1):106-116
pubmed: 31242404
Nat Genet. 2014 Dec;46(12):1251
pubmed: 25418742
Cell. 2002 Sep 20;110(6):673-87
pubmed: 12297042
Exp Cell Res. 2020 Jul 15;392(2):112055
pubmed: 32376286
Trends Cell Biol. 2006 Jul;16(7):376-83
pubmed: 16757171
Nat Rev Mol Cell Biol. 2004 Oct;5(10):816-26
pubmed: 15459662
Mol Biol (Mosk). 2019 Jul-Aug;53(4):648-653
pubmed: 31397438
Cancer Res. 2016 Jun 15;76(12):3446-50
pubmed: 27256564
J Cell Physiol. 2018 Mar;233(3):2257-2269
pubmed: 28708243
PLoS One. 2014 Feb 12;9(2):e88386
pubmed: 24533083
Nat Rev Cancer. 2010 Jan;10(1):9-22
pubmed: 20029421
PeerJ. 2019 Dec 20;7:e8299
pubmed: 31875161
Proc Natl Acad Sci U S A. 2017 Mar 21;114(12):E2337-E2346
pubmed: 28270621
Curr Top Microbiol Immunol. 2011;344:1-24
pubmed: 20512556
Cancer Cell. 2004 Nov;6(5):471-83
pubmed: 15542431
Clin Cancer Res. 1998 Feb;4(2):407-10
pubmed: 9516929
J Cancer. 2019 Aug 28;10(21):5223-5233
pubmed: 31602273
Cancer Lett. 2017 Feb 28;387:61-68
pubmed: 26845449
Anim Genet. 2021 Feb;52(1):138-139
pubmed: 33225458
Mod Pathol. 2005 Sep;18(9):1165-75
pubmed: 15920552
Cell. 2016 Jun 30;166(1):21-45
pubmed: 27368099
Gynecol Oncol. 1997 Mar;64(3):481-6
pubmed: 9062155
Semin Cancer Biol. 2001 Apr;11(2):129-41
pubmed: 11322832
Pathol Int. 2002 Jul;52(7):438-41
pubmed: 12167101
iScience. 2020 Aug 22;23(9):101496
pubmed: 32947124
Cell Death Differ. 2019 Aug;26(8):1453-1466
pubmed: 30361615
Trends Pharmacol Sci. 2007 Oct;28(10):506-11
pubmed: 17822782